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Sulforaphane (SFN), an aliphatic isothiocyanate, is a
known cancer chemopreventive agent. Aiming to inves-
tigate anti-inflammatory mechanisms of SFN, we here
report a potent decrease in lipopolysaccharide (LPS)-
induced secretion of pro-inflammatory and pro-carcino-
genic signaling factors in cultured Raw 264.7 macro-
phages after SFN treatment, i.e. NO, prostaglandin E2,
and tumor necrosis factor . SFN did not directly inter-
act with NO, nor did it inhibit inducible nitric-oxide
synthase enzymatic activity. Western blot analyses re-
vealed time- and dose-dependent reduction of LPS-in-
duced inducible nitric-oxide synthase as well as Cox-2
protein expression, which was suppressed at the tran-
scriptional level. To reveal the target of SFN beyond its
anti-inflammatory action, we performed electrophoretic
mobility shift assay analyses of transcription factor-
DNA binding. Consequently, nuclear factor B (NF-B),
a pivotal transcription factor in LPS-stimulated pro-
inflammatory response, was identified as the key medi-
ator. SFN selectively reduced DNA binding of NF-B
without interfering with LPS-induced degradation of
the inhibitor of NF-B nor with nuclear translocation of
NF-B. Because SFN can interact with thiol groups by
dithiocarbamate formation, it may impair the redox-
sensitive DNA binding and transactivation of NF-B.
Sulforaphane could either directly inactivate NF-B
subunits by binding to essential Cys residues or inter-
act with glutathione or other redox regulators like
thioredoxin and Ref-1 relevant for NF-B function. Our
data provide novel evidence that anti-inflammatory
mechanisms contribute to sulforaphane-mediated can-
cer chemoprevention.
Sulforaphane (SFN)
1 (1-isothiocyanato-(4R)-(methylsulfinyl)
butane: CH3S(O)(CH2)4–NCS) is a naturally occurring can-
cer chemopreventive agent found as a precursor glucosinolate
in cruciferous vegetables like broccoli (1). Chemoprevention
involves preventing, delaying, or reversing carcinogenesis by
intervention with nontoxic compounds, synthetic chemicals, or
natural compounds before malignancy (2). With this respect,
SFN has been shown to prevent 7,12-dimethylbenz[a]anthra-
cene-induced preneoplastic lesions in mouse mammary glands
(3) and rat mammary tumorigenesis (4). These effects were
initially attributed to modulation of carcinogen metabolism by
monofunctional induction of phase II detoxication enzymes and
glutathione (GSH) levels (3) and by inhibition of human and rat
cytochromes P-450 and benzo[a]pyrene-DNA binding (summa-
rized in Ref. 5). Recently, additional mechanisms indicative of
prevention of carcinogenesis at various stages have been re-
ported, including inhibition of 12-O-tetradecanoylphorbol-13-
acetate (TPA)-induced ornithine decarboxylase activity, induc-
tion of cell differentiation, initiation of cell cycle arrest, and
apoptosis in human colon cancer cells (6, 7). Subsequently, SFN
was demonstrated to inhibit azoxymethane-induced aberrant
crypt foci in rat colon as a further indication for its potential to
prevent colon cancer (8).
So far, no data were available regarding anti-inflammatory
effects of SFN, although chronic inflammation and carcinogen-
esis are thought to be mechanistically linked (9). Chronic in-
flammation and infections lead to the up-regulation of a series
of enzymes and signaling proteins in affected tissues and cells.
These pro-inflammatory enzymes, including the inducible
forms of nitric-oxide synthase (iNOS) and cyclooxygenase (Cox-
2), responsible for the elevated levels of NO and prostaglandins
(PGs), respectively, are known to be involved in the pathogen-
esis of many chronic diseases including multiple sclerosis, Par-
kinson’s and Alzheimer’s disease, and colon cancer (10–14).
The constitutive epithelial and neuronal forms of nitric-oxide
synthase contribute relatively little to either inflammation or
carcinogenesis. On the other hand, iNOS plays an important
role in the inflammatory response of tissues to injury and
infectious agents. Although iNOS provides a benefit to the
organism in terms of immune surveillance, aberrant or over-
production of NO has been implicated in the pathogenesis of
cancer via reactive nitrogen oxide species-mediated reactions
like nitrosative deamination of DNA bases, lipid peroxidation,
and DNA strand breaks (15, 16). Elevated levels in the expres-
sion of the inducible Cox-2 have been detected in various tumor
types and may account for excessive PG production (17). In
addition to their role as pro-inflammatory mediators, PGs were
demonstrated to suppress immune functions, to inhibit apop-
tosis, to enhance proliferation, and to increase the invasiveness
of cancer cells (18–20). Consequently, inhibition of expression
and enzymatic activity of Cox-2 and down-regulation of PG
levels is regarded as a rational and feasible strategy in cancer
chemoprevention with first positive results in human trials
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stimulate tumor promotion and progression of initiated cells as
well as of preneoplastic lesions (22). Recently, Fujiki et al.
presented evidence that tumor promotion in TNF- (/)
knock-out mice was significantly suppressed in comparison
with TNF- (/) mice (23). Thus, TNF- can be considered as
an endogenous tumor promoter and a central mediator in can-
cer development.
For our studies, we have used the murine macrophage cell
line Raw 264.7, which can be stimulated with bacterial lipopo-
lysaccharides (LPS) to mimic a state of infection and inflam-
mation. In this report, we summarize novel anti-inflammatory
mechanisms mediated by SFN based on the inhibition of
LPS-mediated induction of iNOS, Cox-2, and TNF-. We have
analyzed the mechanism of the observed inhibition of iNOS
induction by RT-PCR and EMSA analyses of transcription
factor-DNA binding and have identified nuclear factor B (NF-B)
as an important target. These anti-inflammatory properties of SFN
may contribute to its chemopreventive potential.
EXPERIMENTAL PROCEDURES
Chemicals—All cell culture media and supplements were obtained
from Life Technologies, Inc. Fetal bovine serum was from Greiner
Labortechnik GmbH (Frickenhausen, Germany). Primary antibodies
for iNOS (sc-650), Cox-2 (sc-1747), p65 (sc-109A), p50 (sc-114X), IB-
(sc-371), IB- (sc-945), and horseradish peroxidase-conjugated second-
ary antibodies (sc-2004 and sc-2020) and consensus oligonucleotides for
NF-B (sc-2505), AP-1 (sc-2501), and C/EBP (sc-2525) were obtained
from Santa Cruz (Heidelberg, Germany). Alexa 488-coupled fluorescent
anti-rabbit antibody used for immunocytochemistry and SIN-1 were
obtained from Molecular Probes (Mobitec, Go ¨ttingen, Germany).
Vectashield was from Alexis (Gru ¨nberg, Germany). -
32P-Labeled ATP
was purchased from ICN (Costa Mesa, CA). BioTrak TNF- enzyme-
linked immunosorbent assay kit was obtained from Amersham Phar-
macia Biotech. A prostaglandin screen colorimetric kit was purchased
from Cayman Chemical Company (Ann Arbor, MI). RNAclean used for
RNA extraction was from Hybaid AGS (Heidelberg, Germany), and an
Advantage RT for PCR kit and Advantage cDNA and Amplimer kits for
iNOS and GAPDH were purchased from CLONTECH (Heidelberg, Ger-
many). All materials, equipment, and biotinylated marker proteins for
gel electrophoresis were from Bio-Rad. All other chemicals were ob-
tained from Sigma.
Synthesis of SFN—SFN was synthesized following the method of
Kim and Yi (24). 300 mg (2.22 mmol) of ()-1-amino-4-(methylsulfinyl)-
butane, obtained according to Ref. 25 in 98% yield, were dissolved in 10
ml of CH2Cl2, and 515 mg (2.22 mmol) of 1,1-thiocarbonyldi-2(1H)-
pyridone were added at room temperature. The reaction mixture was
stirred for 1 h and then washed with saturated aqueous NaHCO3
solution. The aqueous phase was extracted with 3  30 ml of CH2Cl2.
The organic fractions were combined and dried over Na2CO3, and the
solvent was removed in vacuo. Distillation yielded 250 mg (64%) of a
pale yellow oil. For
1H nuclear magnetic resonance (in CDCl3), : 1.83–
2.02 (m, 4H), 2.59–2.8 (m, 2H), 2.61 (s,
3H), 3.62 (t, J  6.0 Hz, 2H)
(Bruker AC-250-Spectrometer). For
13C NMR (CDCl3), : 20.0, 28.9,
38.6, 44.5, 53.4 (Bruker AC-250-Spectrometer). Formula: C6H11NOS2.
Analysis: Calculated C 40.65, H 6.25, N 7.90, S 36.17; Found: C 40.77,
H 6.50, N 7.96, S 36.39 (Carlo Erba EA 1108-Elemental Analyzer).
Cell Culture—Raw 264.7 murine macrophages were obtained from
the Deutsches Krebsforschungszentrum (Heidelberg, Germany) and
maintained in Dulbecco’s modified Eagle’s medium containing 100
units/ml penicillin G sodium, 100 units/ml streptomycin sulfate, and
250 ng/ml amphotericin B, supplemented with 10% fetal bovine serum
under endotoxin-free conditions at 37 °Ci na5 %C O 2 atmosphere.
Unless otherwise indicated, the cells were preincubated in Dulbecco’s
modified Eagle’s medium containing fetal bovine serum for 24 h. Then
the medium was replaced by serum-free Dulbecco’s modified Eagle’s
medium, and LPSs (from Escherichia coli, serotype O111:B4) were
added at a final concentration of 500 ng/ml.
Inhibition of LPS-mediated iNOS Induction, PGE2 Production, and
TNF- Secretion—Raw macrophages were plated at a density of 2  10
5
cells/well in 96-well plates and incubated overnight. The cells were
treated with test compounds and LPS for 24 h. NO production was
determined via quantitation of nitrite levels in cell culture superna-
tants according to the Griess reaction and compared with a nitrite
standard curve (26). The amount of secreted PGE2 was determined in
1:2000 diluted cell culture supernatants employing a prostaglandin
screen colorimetric assay kit (Cayman) according to the manufacturer’s
protocol. The amount of secreted TNF- was measured in 1:10 diluted
cell culture supernatants using the BioTrak TNF- mouse enzyme-
linked immunosorbent assay system (Amersham Pharmacia Biotech).
Effects on cell growth were estimated by sulforhodamin B staining (27).
IC50 values (half-maximal inhibitory concentration) of LPS-induced
nitrite production, PGE2, or TNF- secretion were generated from the
results of eight serial 2-fold dilutions tested in duplicate.
Inhibition of LPS-induced iNOS Enzyme Activity—Raw macro-
phages were grown in 75-cm
2 tissue culture flasks to 60–70% conflu-
ence, and iNOS expression was induced by treatment with LPS for 12 h.
The cells were washed twice with PBS, harvested by scraping, plated
into 96-well plates (2  10
5 cells/well), and incubated in the presence or
absence of SFN or N-monomethyl-L-arginine, a known inhibitor of NOS
enzyme activity, for another 12 h without further stimulation by LPS.
Cell viability was measured by the MTT assay (28). In addition, iNOS
enzymatic activity was measured in cell lysates essentially as described
by Vodovotz et al. (29).
Western Blot Analyses—Raw macrophages were plated in 60-mm
tissue culture dishes (2.5  10
6 cells/5 ml) and treated as indicated in
the figure legends. The cells were washed with PBS and lysed with
boiling 2 standard lysis buffer. Protein was determined using the BCA
method (30) after precipitation with cold 10% TCA. Total protein
(15–40 g/lane) was electrophoresed on a 7% (iNOS, Cox-2), 10% (p50
and p65), or 12% (IB) reducing SDS-polyacrylamide gel under stand-
ard conditions and electroblotted to polyvinylidene difluoride mem-
branes in 20% methanol, 25 mM Tris, and 192 mM glycine. Equal protein
loading per lane was ensured by staining either a duplicate gel before
blotting or the membrane after blotting. The membranes were blocked
with 1% nonfat milk in Tris-buffered saline (10 mM Tris, pH 7.4, 100 mM
NaCl) containing 0.01% Tween 20 overnight at 4 °C and incubated with
primary antibody (1:400 dilution for IB- and IB- and 1:2500 dilu-
tion for Cox-2, iNOS, p50, and p65 in 1% nonfat milk in Tris-buffered
saline) for1ha t3 7°C or overnight at 4 °C. After thorough washing, the
membranes were incubated with secondary antibodies conjugated with
horseradish peroxidase (1:2500) and streptavidin-horseradish peroxi-
dase (1:2500) for 30 min at 37 °C. The membranes were developed using
a chemiluminescence system. For quantitation of protein expression,
densitometric scans of the obtained autoradiographs were analyzed
using the Lucia G software (Nikon, Du ¨sseldorf, Germany).
RT-PCR—Total RNA from 5  10
6 Raw macrophages (treated as
indicated) was isolated by the guanidinium thiocyanate-phenol-chloro-
form extraction method using RNAclean. 1 g of RNA was transcribed
into cDNA using the Advantage RT for PCR Kit (CLONTECH). cDNAs
of iNOS and GAPDH, respectively, were amplified with the Advantage
cDNA and Amplimer Kits (CLONTECH) for 35 cycles of 45 s at 94 °C,
4 5sa t6 5°C, and 2 min at 72 °C followed by an extension at 72 °C for
7 min. PCR products were separated on 1.8% agarose gels and visual-
ized by ethidium-bromide staining.
Northern Blot Analysis of ODC mRNA Expression—Raw cells were
grown in 60-mm cell culture dishes (2.5  10
6 cells/5 ml) and treated
with LPS and SFN as indicated. Total RNA was isolated with RNAclean
(Hybaid-AGS). RNA samples (20 g/lane) were separated by electro-
phoresis on a 1.2% agarose gel containing 6.7% formaldehyde according
to Sambrook et al. (31) and vacuum-blotted to a nylon membrane (Zeta
Probe GT, Bio-Rad) in 20 SSC. The membrane was baked at 80 °C for
1 h and prehybridized in 0.25 M Na2HPO4, pH 7.2, containing 7% SDS.
Hybridization was performed at 65 °C for 18 h with an ODC c-DNA
probe labeled with [-
32P]dCTP using a Random Primer labeling kit
(Stratagene). After thorough washing with washing solution (20 mM
Na2HPO4, pH 7.2, 5–1% SDS depending on stringency), the membrane
was exposed to x-ray film.
Electrophoretic Mobility Shift Assay—Raw macrophages were plated
in 60-mm dishes (2.5  10
6 cells/5 ml). The cells were treated with SFN
at the indicated concentrations and stimulated with LPS for 45 min
(NF-B and AP-1) or up to 4 h (CEBP/), washed once with PBS,
scraped into 0.5 ml cold PBS, and pelleted by centrifugation. Cytosolic
and nuclear protein fractions were extracted as described previously
(32). Binding reactions were performed at 37 °C for 15 min in 20 lo f
reaction buffer containing 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM
EDTA, 10% glycerol, 0.5 or 1 g of poly(dI-dC), 1 mM dithiothreitol, and
30,000 cpm
32P-labeled oligonucleotide probes for NF-B, AP-1, and
C/EBP. DNA-protein complexes were separated from unbound DNA
probe on native 6% polyacrylamide gels at 75V in 0.5 TBE buffer. The
gels were vacuum-dried for1ha t8 0°C and exposed to x-ray film at
80 °Cf o r4t o2 4h .F o rin vitro binding studies, nuclear protein from
LPS-stimulated Raw 264.7 macrophages was incubated with SFN or
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ture before the labeled probe was added, and binding reaction and
electrophoresis were conducted as described above.
Immunofluorescent Detection of NF-B Localization—Raw macro-
phages were grown on glass coverslips overnight. Cells were treated
with Me2SO alone, Me2SO and LPS (500 ng/ml), or 20 M SFN and LPS
(500 ng/ml), respectively, for 45 min. The cells were fixed with ice-cold
acetone for 2 min, rinsed in PBS, and permeabilized with 0.4% Triton
X-100 in PBS. Unspecific binding sites were blocked with 5% bovine
serum albumin in PBS. After incubation with anti-p65 and anti-p50,
respectively, overnight at 4 °C and washing with PBS, the Alexa 488-
conjugated secondary antibody was applied for1ha troom tempera-
ture. 4,6-Diamidino-2-phenylindole dihydrochloride-stained and
Vectashield-mounted cells were analyzed under a Zeiss fluorescence
microscope. Digital images were acquired with an AxioCam color digital
camera and processed with the Axiovision Rel. 2.05 software package
(Carl Zeiss, Go ¨ttingen, Germany).
Determination of GSH Levels—Raw macrophages were seeded in
96-well plates (1  10
5cells/well). SFN (final concentration, 0.4–50 M)
was added 1–24 h prior to determination of total GSH and protein
levels. The plates were washed three times with PBS and stored at
80 °C until analyzed. GSH was measured essentially as described
previously (3) and normalized to protein concentrations determined
using the BCA method (30).
RESULTS
The aim of this study was to analyze potential anti-inflam-
matory properties of SFN and to elucidate the underlying
mechanisms of action. We used the murine macrophage cell
line Raw 264.7, which releases NO, PGs, and pro-inflammatory
cytokines such as TNF-, IL-1, IL-6, and IL-12 upon stimula-
tion with LPS, thus providing a suitable model for studying
inflammatory response in cultured cells.
Inhibition of LPS-mediated NO Generation, PGE2 Produc-
tion, and TNF- Secretion—Treatment of Raw macrophages
with SFN caused a dose-dependent inhibition of LPS-induced
NO generation (measured via nitrite levels in cell culture su-
pernatants by the Griess reaction), PGE2 production and
TNF- secretion with apparent IC50 values of 0.7, 1.4, and 7.8
M, respectively (Fig. 1). The inhibition of these processes was
not due to reduction of cell viability. To exclude direct NO-
scavenging potential of SFN or interference with the Griess
reaction, SFN was incubated for3ha troom temperature with
the NO-donor SIN-1 (7.5 mM in H2O), which spontaneously
releases NO under slightly alkaline conditions in vitro.I na
concentration range of 0.02–2.5 mM, nitrite levels of SFN-
treated samples were similar to that of the Me2SO solvent
control (Fig. 2).
iNOS Enzyme Activity—Focussing on the effect of SFN on
NO production, we analyzed whether the inhibitory effect of
SFN was due to inhibition of iNOS enzymatic activity. SFN at
concentrations of 25 and 50 M reduced NO levels in a cellular
assay by 20 and 25% in comparison with the control; however,
lowered nitrite levels were attributed to a concomitant reduc-
tion in cell viability rather than enzyme inhibition (Fig. 3, left
panel). In contrast, N-monomethyl-L-arginine, an enzyme sub-
strate analogue, inhibited iNOS enzyme activity by a maxi-
mum of 60% in a concentration range of 0.8–100 M without
any signs of toxicity (Fig. 3, right panel). These findings were
confirmed in a cell-free assay using lysates of LPS-stimulated
Raw macrophages as a source of iNOS and L-arginine as a
substrate (specific activity, 8 nmol nitrite/mg/h). Nitrite levels
were reduced 8.8% by 20 M SFN and 46.2% by 100 M N-
monomethyl-L-arginine, respectively.
Influence on Protein and mRNA Expression—A potential
inhibitory influence of SFN on LPS-stimulated protein expres-
sion was measured by Western blot analyses. SFN suppressed
LPS-mediated up-regulation of iNOS protein in a time-depend-
ent manner (Fig. 4A). In the Me2SO control, iNOS levels were
detectable as early as 6 h after LPS addition, whereas 5 M
SFN completely inhibited iNOS induction at all time points.
Similar results were obtained when LPS-mediated Cox-2 ex-
pression was measured. Dose-dependent effects of SFN were
analyzed 12 h post LPS stimulation (Fig. 4C). In good correla-
tion with the reduction of NO release, 0.8 and 1.5 M SFN
significantly lowered iNOS protein levels by 27 and 61% in
comparison with the control. LPS-induced Cox-2 expression
was also inhibited in a dose-dependent manner, whereas TPA-
mediated Cox-2 expression in Raw macrophages was not af-
fected by SFN (Fig. 4E). When 5 M SFN was added at different
time points after LPS stimulation, inhibitory effects on iNOS
and Cox-2 expression and NO production were no longer de-
tectable when the time interval between LPS stimulation and
SFN addition exceeded 4 h (Fig. 5). We concluded that SFN
targets an early event in the signal transduction pathway
between LPS stimulation and protein induction, presumably at
the transcriptional level, and analyzed the effects of SFN on
iNOS mRNA expression by RT-PCR (Fig. 4, B and D). In close
correlation with the results obtained at the protein level, SFN
potently down-regulated iNOS mRNA expression in a time-
and dose-dependent manner.
Apart from induction of pro-inflammatory proteins, LPS
treatment of Raw macrophages has previously been shown to
induce levels of ornithine decarboxylase (ODC) (33). ODC as a
key enzyme in polyamine synthesis is overexpressed in many
tumor types and accounts for enhanced tumor promotion. By
Northern blot analyses, we could demonstrate a maximum of
ODC mRNA expression in Raw macrophages 5 h after LPS
treatment (Fig. 6A). SFN in a concentration range of 0.4–25 M
was not able to suppress the observed LPS-mediated ODC
mRNA induction (Fig. 6B).
Inhibition of NF-B DNA Binding Activity in Vivo—To fur-
ther investigate the mechanism of SFN-mediated inhibition of
FIG.1 .Inhibition of LPS-induced generation of NO, PGE2, and
TNF-. Raw macrophages were treated with SFN or Me2SO and stim-
ulated with LPS for 24 h. Nitrite, as a measure of NO production ( ),
secreted PGE2 (f), and TNF- (ƒ), was determined in cell culture
supernatants (levels in unstimulated controls: 0.45  0.17 nmol nitrite/
ml, n  5; 0.25  0.1 ng PGE2/ml, n  2; 0.5 ng TNF-/ml, n  2; after
LPS stimulation: 29.1  4.1 nmol nitrite/ml, n  5; 5.9  0.5 ng
PGE2/ml, n  2; 18.2  3.0 ng TNF-/ml, n  2). Effects of SFN on cell
growth were measured by SRB staining ().
FIG.2 .Determination of NO scavenging activity of SFN. SFN in
a concentration range of 0–2.5 mM was incubated for3ha troom
temperature with 7.5 mM of the NO donor SIN-1 in H2O. The nitrite
levels were determined via the Griess reaction.
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to transactivate iNOS, Cox-2, and TNF-. EMSA analyses
demonstrated a selective reduction of NF-B DNA binding in
nuclear extracts obtained from LPS-stimulated Raw macro-
phages treated with 10 and 20 M SFN, whereas DNA binding
of transcription factors AP-1 and C/EBP was not influenced
(Fig. 7).
Degradation of IB—In unstimulated cells, NF-B is seques-
tered in the cytosol by its inhibitor IB, which upon LPS stim-
ulation is phosphorylated by IB kinase, ubiquitinated, and
rapidly degraded via the 26 S proteasome, thus releasing
NF-B (34, 35). SFN (10 M) had no influence on LPS-induced
degradation of IB- and IB-, constituting the IB complex.
30 min post LPS-exposure, IB- was not detectable in protein
lysates of either treated or untreated macrophages. Rather,
SFN retarded de novo synthesis of IB-, which reappeared
180 min after LPS stimulation in control samples (Fig. 8A).
Because IB- transcription is B-dependent (36), these find-
ings were consistent with SFN-mediated inhibition of NF-B
DNA binding. IB- degradation was observed in both SFN-
treated and Me2SO control cells 360 min after LPS stimulation
(Fig. 8B).
Nuclear Translocation of NF-B—The next step to investi-
gate was whether SFN prevented the most prominent subunits
of NF-B, p50 and p65, from translocation to the nucleus after
release from IB. Immunocytochemical detection of p65 re-
FIG.3 . Determination of iNOS enzyme activity. Raw macro-
phages were stimulated with LPS for 12 h. Then Me2SO, SFN, or
N-monomethyl-L-arginine (NMA) were added in LPS-free medium. Af-
ter further incubation for 12 h, the nitrite levels ( ) were determined in
cell culture supernatants, and inhibitory potential was calculated in
comparison with the Me2SO control (25.8  2.3 nmol nitrite/ml; n  3).
Cell viability was measured by the MTT assay (ƒ).
FIG.4 . Influence on time- and dose-dependent inhibition of
iNOS and Cox-2 protein and iNOS mRNA expression. A and B,
time course. Raw macrophages were treated with 5 M SFN ()o r
Me2SO () and stimulated with LPS for 2–12 h as indicated. C and D,
dose response. Raw macrophages were treated with Me2SO () or 0.4 to
25 M SFN, respectively, as indicated and were stimulated with LPS
() for 12 h. Western blot analyses of iNOS (upper panel) and Cox-2
(lower panel) protein expression (A and C), RT-PCR amplification of
iNOS (upper panel) and GAPDH (lower panel) mRNA (B and D). E,
Cox-2 induction by TPA. Raw macrophages were treated with Me2SO
()o r0 . 4–25 M SFN, respectively, and stimulated with 60 ng/ml TPA
() for 12 h. Whole cell lysates were subjected to Western blot analysis
of Cox-2 expression.
FIG.5 .Effect of SFN addition at different time points after
LPS stimulation. Raw macrophages were stimulated with LPS (500
ng/ml). SFN (5 M) was added simultaneously or at time points up to 8 h
after LPS exposure as indicated. A, nitrite as a measure of NO produc-
tion ( ) was determined in cell culture supernatants. Effects of SFN on
cell growth were measured by SRB staining (f). B, iNOS and Cox-2
protein expression was analyzed by Western blotting.
FIG.6 . Influence on ODC mRNA induction. A, Northern blot
hybridization of RNA samples from cultured Raw macrophages treated
with LPS for 3 to7ha sindicated using an ODC cDNA probe (upper
panel). Lower panel, ethidium bromide-stained gel. B, Northern blot
hybridization of RNA samples from Raw macrophages using an ODC
probe (upper panel). Lower panel, ethidium bromide-stained gel. The
cells were treated with LPS (500 ng/ml) and varying concentrations of
SFN as indicated for 5 h.
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cells after LPS stimulation (Fig. 9A). p50 was localized in
cytosol and nuclei of unstimulated cells and was not influenced
by LPS stimulation or SFN treatment (Fig. 9B). Western blot
analyses with nuclear fractions of correspondingly treated cells
and p50- and p65-specific antibodies showed consistent results
(Fig. 10).
Inhibition of NF-B Binding by Exogenous SFN—In addition
to preventing NF-B binding to its consensus sequence in intact
cells, SFN exogenously added to nuclear protein was capable of
reducing the formation of the DNA-protein complex in a dose-de-
pendent manner (Fig. 11). This inhibitory effect was preventable
by preincubation of SFN with an excess of mercaptoethanol,
suggesting a thiol-dependent modification of NF-B subunits by
SFN. Identical results were obtained when cytosolic proteins
(4–5 g) of untreated cells, providing the NF-BIB complex,
were preincubated in aqueous 0.8% deoxycholate solution con-
taining 1.1% Igepal for 10 min on ice to release active NF-B
dissociated from its inhibitor (data not shown).
Effect of Cellular Glutathione Levels on LPS-induced Nitrite
Levels—To further investigate a potential thiol dependence of
NF-B inhibition, we were interested whether changes in cel-
lular GSH levels after pretreatment with SFN for different
time periods would modulate SFN-mediated inhibition of iNOS
induction. Total GSH levels initially dropped to 43% of control
values (75.5 nmol/mg protein) after4ho fpretreatment with
12.5 M SFN (Fig. 12A). Then the GSH-depleting effect was
reversed by induction of GSH, resulting in 2-fold elevated lev-
els after 24 h (149.5 nmol/mg protein). When LPS was added
under high GSH conditions, the observed IC50 value for SFN-
mediated inhibition of NO release was doubled. To relate dose-
dependent modulation of GSH levels to the inhibition of NO
production, we plotted the values of the area under the (induc-
tion or inhibition) curve at each time point against each other
and found a significant correlation (r
2  0.96) (Fig. 12B).
FIG.7 . Electrophoretic mobility shift assay of NF-B, AP-1,
and C/EBP DNA-binding capacity. A, raw macrophages were
treated with Me2SO () or SFN (as indicated) and stimulated with LPS
() for 45 min before nuclear protein was isolated. DNA binding was
analyzed using specific
32P-labeled oligonucleotide probes for NF-B
(upper panel) or AP-1 (lower panel). B, cells were treated with Me2SO
()o r1 5M SFN () and stimulated with LPS for 0–240 min before
nuclear protein was isolated and C/EBP DNA binding was analyzed.
Specificity was demonstrated by co-incubation with a 25-fold excess of
unlabeled specific (lane s) or unspecific probe (lane u; AP-1 for NF-B,
NF-B for AP-1 and C/EBP) for competition (Comp.).
FIG.8 . IB degradation. Raw macrophages were treated with
Me2SO ()o r1 0M SFN () and stimulated with LPS for the indicated
periods of time. Total protein was subjected to Western blot analyses
using anti-IB- antibody (A) and anti-IB- antibody (B).
FIG.9 .Immunocytochemical analysis of nuclear translocation
of NF-B. Raw macrophages were grown on coverslips, treated with
Me2SO (panels a–d and g–j)o r2 0M SFN (panels e, f, k, and l),
stimulated with LPS for 45 min (panels c–f and i–l), fixed, and subjected
to immunocytochemical analysis with anti-p65 (A) or anti-p50 (B) an-
tibody, respectively, and Alexa 488-conjugated secondary antibody (up-
per panels). Nuclei were stained with DAPI (lower panels). Magnifica-
tion, 400.
FIG. 10. Western blot analyses of nuclear translocation of NF-
B. Raw macrophages were treated with LPS (500 ng/ml) () and 10 or
20 M SFN, respectively, for 45 min before nuclear protein fractions
were subjected to Western blot analyses of p65 (upper panel) and p50
(lower panel) proteins.
FIG. 11. Inhibition of NF-B DNA binding by exogenous SFN.
Nuclear protein from LPS-stimulated cells was incubated for 75 min
with 0-, 10-, or 25-fold excess of specific competitor, 0.25–2.0 mM exog-
enous SFN as indicated, or 2.0 mM SFN preincubated with 142 mM
mercaptoethanol (ME) for 15 min, respectively. The arrow indicates the
position of the NF-B (p50/p65) band. ns, nonspecific binding.
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The present report provides the first evidence that anti-
inflammatory mechanisms could contribute to SFN-mediated
cancer chemoprevention. We have demonstrated that SFN
down-regulates LPS-mediated induction of iNOS and Cox-2
expression and TNF- secretion in cultured Raw macrophages.
iNOS (and presumably also Cox-2 and TNF-) induction was
repressed at the transcriptional level, and we focused our re-
search on elucidating the underlying molecular mechanisms.
Treatment of Raw macrophages with endotoxins like LPS
results in the coordinate activation of a series of signaling
mediators, including NF-B, cAMP, the cJun/cFos heterodimer
AP-1, or nuclear factor interleukin-6 (NF-IL6, also known as
C/EBP), transactivating the transcription of LPS-responsive
genes after binding to respective binding sites or enhancer
elements. As a first approach to identify a target for SFN
action, we compared known cis-acting elements in the promot-
er/enhancer region of iNOS (37–39), Cox-2 (40, 41), and TNF-
(literature cited in Ref. 42), assuming that a common LPS-
activated nuclear factor might be affected by SFN. We identi-
fied binding sites for the NF-B and C/EBP families of tran-
scription factors in the promoter regions of all three genes. In
macrophages, NF-B is known to play a critical role in the
regulation of genes involved in immune response and to coor-
dinate the expression of pro-inflammatory proteins including
iNOS, Cox-2, and TNF- (36, 43). C/EBP was initially identi-
fied as an IL-1-induced transcription factor (44) and was re-
centlyshowntobeinvolvedinsolublephospholipaseA2-receptor-
dependent Cox-2 up-regulation in NIH3T3 cells (45). Both
transcription factors have been reported to interact in the
transcriptional regulation of genes (46). EMSA analyses re-
vealed that DNA binding of NF-B was inhibited by SFN (Fig.
7A), whereas C/EBP DNA binding was not affected and there-
fore not further investigated (Fig. 7B). LPS treatment of Raw
macrophages has been shown to result in cAMP/cAMP-respon-
sive element-mediated induction of ODC. We excluded a possi-
ble interference of SFN with cAMP/cAMP-responsive element-
dependent transcription because SFN did not inhibit ODC
mRNA induction. This is consistent with our findings that SFN
suppresses LPS-mediated gene expression mainly via inhibi-
tion of NF-B activity. The ODC promoter does not contain any
known NF-B binding site, and ODC transcription is therefore
not affected by SFN.
To gain more information on the selectivity of SFN for NF-
B, we stimulated Raw macrophages with the tumor promoter
TPA. TPA is a known activator of protein kinase C and was
shown to up-regulate Cox-2 protein levels in Raw macrophages
mainly through AP-1 transactivation (47), without concomitant
induction of iNOS. This was ascribed to a lack of Raw macro-
phages in protein kinase C essential for activation of NF-B
(48). Under these conditions, SFN did not inhibit Cox-2 protein
expression (Fig. 4E), indicating that SFN would not interfere
with AP-1 transactivating activity. These findings were con-
firmed by EMSA analyses (Fig. 7A). Consistently, SFN was
reported to enhance AP-1-supported expression of phase II
detoxication enzymes by increasing extracellular signal-regu-
lated kinase 2 phosphorylation and kinase activity in hepatoma
cells (49). Interestingly, the triterpene ursolic acid has been
demonstrated recently to suppress Cox-2 transcription in hu-
man mammary epithelial cells by inhibition of TPA-mediated
induction of protein kinase C, extracellular signal-regulated
kinase 1/2, c-Jun N-terminal kinase, and p38 mitogen-acti-
vated protein kinases (50).
Having established NF-B as a target of SFN, we focused on
the mechanism of inactivation. Other than agents like theafla-
vin, ()-epigallocatechin gallate, or resveratrol, which have
been shown to impair IB degradation (51–53), SFN was inac-
tive in this respect. Rather, in SFN-treated cells, activated
NF-B translocated to the nucleus, but DNA binding was im-
paired. We noticed that concentrations of SFN required to
prevent activated NF-B from binding to its consensus se-
quence were essentially higher than those required to inhibit
LPS-mediated iNOS induction (i.e. 10–20 M when added prior
to LPS stimulation or 1–2m M when added exogenously to
activated NF-B). This might partially be due to different in-
cubation periods (45 min for NF-B activation versus 12–24 h
in iNOS induction experiments). Also, SFN has been shown
recently to accumulate in murine hepatoma cells treated with
5 M SFN up to a concentration of 900 M within 30 min (54).
This intracellular accumulation was attributed to a reversible
binding of SFN to GSH by dithiocarbamate formation. There-
fore, intracellular concentrations of 1 mM in our system are
feasible but have to be experimentally confirmed.
Inhibition of NF-B DNA binding was preventable by prein-
cubation of SFN with an excess of mercaptoethanol, suggesting
a direct, reversible and thiol-dependent modification of NF-B
subunits or relevant co-factors by SFN. This prompted us to
investigate how SFN-mediated effects on intracellular thiol
levels (using GSH as a marker) might influence anti-inflam-
matory activities. In Raw macrophages, preincubation with
SFN for various time periods initially resulted in GSH deple-
FIG. 12. Effect of cellular GSH levels on LPS-induced nitrite
levels. A, Raw macrophages were seeded in three 96-well plates and
incubated for 1–24 h with SFN in a concentration range of 0.4–50 M
before total GSH and protein levels were determined at time 0 (total
GSH levels in untreated cells at time 0: 76  5 nmol/mg protein, n  3;
black bars, GSH levels after treatment with 12.5 M SFN). At time 0,
SFN-treated cells were stimulated with LPS for another 24 h, and the
IC50 values for inhibition of NO release were determined (gray bars). B,
for each time point, GSH and NO levels were plotted against SFN
concentrations. The unprocessed area under the curve (AUC) values for
GSH and NO, respectively, were obtained from the area xmin to xmax
function in the TableCurve
TM XY table status window (Jandel Scientif-
ic). For each time point, these values were plotted against each other,
and a correlation coefficient of r
2  0.96 was obtained.
Anti-inflammatory Activity of Sulforaphane 32013tion, which was reversed by an autoregulatory feedback induc-
tion of GSH with 2-fold elevated levels after 24 h (Fig. 12A).
LPS treatment under these conditions resulted in a 2-fold
higher IC50 value of SFN with respect to inhibition of NO
release. Identical results were reported when diethylmaleate
was employed to deplete GSH via a glutathione S-transferase-
mediated step (55). We quantitatively compared dose-depend-
ent effects of SFN on GSH and nitrite levels at each time point
by area under (induction or inhibition) curve values and ob-
tained a significant correlation between both parameters (r
2 
0.96) (Fig. 12B). Based on these observations, we speculated
that elevated GSH levels might compete with essential Cys
residues either of NF-B subunits (56) or other redox regula-
tors relevant for NF-B function for interaction with SFN. At
conditions of low GSH, SFN would predominantly interact with
these factors and exert a stronger inhibitory effect, whereas
higher GSH concentrations would render it less accessible for
other reaction partners. The fact that elevated GSH concentra-
tions weaken but do not totally abolish the inhibitory effect of
SFN favors this possibility.
NF-B is a redox-sensitive transcription factor tightly regu-
lated by the intracellular redox status, which is maintained
mainly by the ratio of reduced and oxidized GSH. NF-B re-
quires a high GSSG/GSH ratio for activation and nuclear trans-
location but depends on a reducing milieu for binding to its
consensus site (57, 58). Because SFN did not inhibit nuclear
translocation, we hypothesized that disturbance of intranu-
clear redox conditions might contribute to the inhibition of
NF-B DNA binding. Reducing conditions in the nucleus are
modulated by redox regulators including thioredoxin (TRX)
and redox factor-1 (Ref-1) (59). TRX has been found to be
particularly important for gene expression because it facilitates
protein-nucleic acid interactions by reducing Cys residues in
the DNA binding loop of several transcription factors essential
for recognition of binding sites through electrostatic interac-
tions with specific DNA bases (60, 61). A direct association
between TRX and the NF-B p50 subunit was suggested by in
vitro cross-linking assays (62). Our own preliminary results
underline the importance of reduced TRX in LPS-mediated
iNOS induction, because 1-chloro-2,4-dinitrobenzene, an inhib-
itor of thioredoxin reductase (63), inhibited NO release after
LPS stimulation with an IC50 value of 5.5 M and synergisti-
cally lowered the IC50 value obtained with SFN.
2 Ref-1 is a
multifunctional protein that not only functions as a redox fac-
tor maintaining transcription factors in an active reduced state
but is also responsible for repair of apurinic sites as a part of
base excision repair (64). Active Ref-1 is recycled via its inter-
action with TRX, which acts as a hydrogen donor polypeptide.
TRX and Ref-1 were found to act synergistically in the regula-
tion of p50 DNA binding activity (65). A recent study employing
high performance affinity bead chromatography suggested a
direct interaction of Ref-1 with the quinone derivative E3330
(66). E3330 was originally developed as an anti-inflammatory
drug and, in good agreement with our results with SFN, sup-
pressed NF-B transactivation without affecting degradation
of IB or nuclear translocation of NF-B (67). Considering the
similarities between SFN and E3330 with regard to inhibition
of NF-B activity, Ref-1 could be regarded as a potential target
of SFN.
Taken together, our data indicate that SFN possesses anti-
inflammatory activity, resulting in down-regulation of LPS-
stimulated iNOS, Cox-2, and TNF- expression in Raw macro-
phages. We conclude that the major mechanism of SFN action
in this model is inhibition of NF-B DNA binding and of trans-
activation of B-dependent genes, presumably through modu-
lation of intracellular redox conditions via dithiocarbamoyla-
tion of essential thiol groups involved in the activation of NF-
B. Further studies are warranted to elucidate the relevance of
these anti-inflammatory properties for SFN-mediated cancer
chemopreventive efficacy.
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